4.7 Article

Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study

期刊

JOURNAL OF NEUROLOGY
卷 269, 期 9, 页码 4808-4816

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00415-022-11118-7

关键词

Multiple sclerosis; Teriflunomide; Real-world; No evidence of disease activity (NEDA); Efficacy; Safety

资金

  1. National Key Research and Development Program of China [2016YFC0901500]
  2. CAMS Innovation Fund for Medical Sciences (CIFMS) [2020-12M-CoV19-001]
  3. Peking Union Medical College Education Reform Fund [2017zlgc0121]
  4. Peking Union Medical College Deposition Research Fund [ZC201904188]

向作者/读者索取更多资源

This study aimed to explore the efficacy, risk factors, safety, and persistence of teriflunomide in patients with relapsing-remitting multiple sclerosis (RRMS). The results showed that teriflunomide was effective and well-tolerated in treatment-naive RRMS patients. Male patients with high relapse rates and disability before treatment were more likely to experience treatment failure.
Objectives To explore efficacy, risk factors, safety, and persistence of teriflunomide in relapsing-remitting multiple sclerosis (RRMS) cohort. Methods This prospective, observational cohort study included 217 consecutive teriflunomide treated RRMS patients, 192 of which with at least 3-month persistence on teriflunomide were included in effectiveness and risk factor analyses. Multivariate Cox proportional regression analysis was performed to identify factors associated with failure of no evidence of disease activity (NEDA) 3. Results At baseline 82% patients were treatment naive while 18.0% interferon-beta 1b treated patients had stopped treatments for more than 1 year. After treatment, 79.0% patients achieved NEDA 3 at 12-month, mean annualized relapse rate (ARR) reduced significantly (0.79 +/- 0.80 vs 0.16 +/- 0.70; P < 0.001), and mean expanded disability status score (EDSS) remained stable (1.40 +/- 1.67 vs 1.56 +/- 1.88; P > 0.05). Male sex (hazard ratio [HR] 1.856; 95% confidence interval [CI] 1.118-3.082, P < 0.05), baseline EDSS score >= 4 (HR 2.682; 95% CI 1.375-5.231, P < 0.01), and frequent relapses before treatment (HR 3.056; 95% CI 1.737-5.377, P < 0.01) were independent factors significantly associated with failure of NEDA 3. The most frequent adverse events (AEs) were hair thinning, alanine aminotransferase (ALT) elevation, and leukopenia, the latter two most commonly lead to teriflunomide discontinuation during the first 3 months. Persistence rates at 6, 12, and 24 months after teriflunomide initiation were 86.9%, 72.4%, and 52.8%, respectively. Conclusions Our results support efficacy and tolerability of teriflunomide for treatment-naive RRMS patients in real-world practice. Female patients, patients with less relapses and less disability before treatment are most likely to benefit from teriflunomide treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据